PT1814521E - Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes - Google Patents
Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes Download PDFInfo
- Publication number
- PT1814521E PT1814521E PT05808842T PT05808842T PT1814521E PT 1814521 E PT1814521 E PT 1814521E PT 05808842 T PT05808842 T PT 05808842T PT 05808842 T PT05808842 T PT 05808842T PT 1814521 E PT1814521 E PT 1814521E
- Authority
- PT
- Portugal
- Prior art keywords
- dry powder
- powder inhaler
- modified particles
- particles
- inhaler formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0425758.0A GB0425758D0 (en) | 2004-11-23 | 2004-11-23 | Preparation of pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1814521E true PT1814521E (pt) | 2010-04-16 |
Family
ID=33548732
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT101515765T PT2174653E (pt) | 2004-11-23 | 2005-11-23 | Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes |
PT101790731T PT2311434E (pt) | 2004-11-23 | 2005-11-23 | Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes |
PT05808842T PT1814521E (pt) | 2004-11-23 | 2005-11-23 | Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT101515765T PT2174653E (pt) | 2004-11-23 | 2005-11-23 | Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes |
PT101790731T PT2311434E (pt) | 2004-11-23 | 2005-11-23 | Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes |
Country Status (16)
Country | Link |
---|---|
US (4) | US20080127972A1 (pt) |
EP (4) | EP1814521B1 (pt) |
JP (2) | JP5339401B2 (pt) |
CN (2) | CN101106975A (pt) |
AT (1) | ATE456363T1 (pt) |
CA (1) | CA2589514C (pt) |
DE (1) | DE602005019192D1 (pt) |
DK (2) | DK2174653T3 (pt) |
ES (3) | ES2340599T3 (pt) |
GB (1) | GB0425758D0 (pt) |
HU (1) | HUE027465T2 (pt) |
IN (1) | IN2014CN04336A (pt) |
PL (3) | PL2311434T3 (pt) |
PT (3) | PT2174653E (pt) |
SI (2) | SI2311434T1 (pt) |
WO (1) | WO2006056812A1 (pt) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2283818B1 (en) | 2000-11-30 | 2017-08-02 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US7638138B2 (en) * | 2003-02-21 | 2009-12-29 | Translational Research, Ltd. | Compositions for nasal administration of pharmaceuticals |
CA2519287A1 (en) | 2003-03-27 | 2004-10-14 | Bioactis Limited | Powder medicine applicator for nasal cavity |
US20120321717A1 (en) * | 2003-04-14 | 2012-12-20 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
WO2006016530A1 (ja) * | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
GB0621957D0 (en) * | 2006-11-03 | 2006-12-13 | Vectura Group Plc | Inhaler devices and bespoke pharmaceutical compositions |
WO2008078730A1 (ja) | 2006-12-26 | 2008-07-03 | Translational Research, Ltd. | 経鼻投与用製剤 |
AU2008240158B2 (en) * | 2007-04-11 | 2014-07-10 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
GB0712316D0 (en) * | 2007-06-26 | 2007-08-01 | Entripneur Ltd | A novel powder and its method of manufacture |
WO2009079078A1 (en) | 2007-12-14 | 2009-06-25 | Labogroup S.A.S. | Delivering aerosolizable food products |
MX2011000405A (es) | 2008-07-18 | 2011-03-04 | Prosonix Ltd | Proceso para mejorar la cristalinidad. |
ES2625260T5 (es) | 2009-03-26 | 2020-07-29 | Pulmatrix Operating Co Inc | Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares |
GB0905840D0 (en) * | 2009-04-06 | 2009-05-20 | Sagentia Ltd | Apparatus and methods |
US20120101077A1 (en) * | 2009-04-24 | 2012-04-26 | Schering Corporation | Agglomerate formulations useful in dry powder inhalers |
JP2012526726A (ja) * | 2009-05-15 | 2012-11-01 | 株式会社新日本科学 | 薬物動態が改善された鼻腔内用薬学的組成物 |
GB2472327B (en) | 2009-07-31 | 2013-03-13 | Shin Nippon Biomedical Lab Ltd | Intranasal granisetron and nasal applicator |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
GB0918431D0 (en) | 2009-10-21 | 2009-12-09 | Prosonix Ltd | Process for improving crystallinity |
PL2560611T3 (pl) * | 2010-04-21 | 2018-05-30 | Chiesi Farmaceutici S.P.A. | Sposób wytwarzania cząstek o zredukowanych ładunkach eIektrostatycznych |
CN102309456B (zh) * | 2010-07-02 | 2013-05-01 | 北京化工大学 | 一种厄贝沙坦纳微复合粉体与片剂及其制备方法 |
EP2448571B1 (en) | 2010-08-30 | 2013-06-12 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
CN103200938B (zh) * | 2010-08-30 | 2018-07-31 | 普马特里克斯营业公司 | 干燥粉末配方及用于治疗肺部疾病的方法 |
ES2899621T3 (es) * | 2010-09-29 | 2022-03-14 | Pulmatrix Operating Co Inc | Polvos secos catiónicos que comprenden sal de magnesio |
CA2812414C (en) | 2010-09-29 | 2020-09-22 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
ITMI20120092A1 (it) * | 2012-01-26 | 2013-07-27 | Micro Macinazione S A | Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia |
JP2015509788A (ja) * | 2012-02-29 | 2015-04-02 | パルマトリックス,インコーポレイテッド | 吸入に適した乾燥粉末 |
PL2834244T3 (pl) | 2012-03-13 | 2017-01-31 | Respivert Limited | Krystaliczne inhibitory kinaz PI3 |
KR20140147891A (ko) | 2012-04-13 | 2014-12-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 응집체 입자 |
CN103570610B (zh) * | 2012-07-18 | 2017-08-11 | 重庆华邦制药有限公司 | 一种罗氟司特微粒的制备方法 |
CN103588846B (zh) * | 2012-08-15 | 2016-08-03 | 重庆华邦制药有限公司 | 一种丙酸氟替卡松微粒的制备方法及其用途 |
WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
JP6116206B2 (ja) * | 2012-11-26 | 2017-04-19 | クリニプロ株式会社 | 吸入用パウダーの製造方法 |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
JP6473738B2 (ja) | 2013-04-01 | 2019-02-20 | パルマトリックス,インコーポレイテッド | チオトロピウム乾燥粉末 |
ITMI20130572A1 (it) * | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
WO2014178891A1 (en) * | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
DK3409270T3 (da) | 2013-07-11 | 2021-04-26 | Chiesi Farm Spa | Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation |
EP3054948B1 (en) * | 2013-10-08 | 2020-08-12 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
CN112656780A (zh) * | 2014-02-20 | 2021-04-16 | 奥迪托皮克股份有限公司 | 用于吸入的干粉制剂 |
BR112016022598A8 (pt) | 2014-04-04 | 2021-06-29 | Ai Therapeutics Inc | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso |
EP3166641B1 (en) | 2014-07-09 | 2018-09-12 | Arven Ilac Sanayi Ve Ticaret A.S. | A process for the preparation of formulations for inhalation |
CN116687887A (zh) * | 2014-07-31 | 2023-09-05 | 维克图拉公司 | 用于吸入的干粉制剂 |
TN2017000077A1 (en) | 2014-09-09 | 2018-07-04 | Vectura Ltd | Formulation comprising glycopyrrolate, method and apparatus |
EP3209330B1 (en) | 2014-10-07 | 2022-02-23 | AI Therapeutics, Inc. | An inhalable sirolimus formulation for the treatment of pulmonary hypertension |
US20160119692A1 (en) * | 2014-10-24 | 2016-04-28 | Sunshine Partners LLC | Interactive system and method for viewer selection of objects in context while viewing television |
DK3212212T3 (da) | 2014-10-31 | 2020-12-21 | Univ Monash | Pulverformulering |
PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
US9585835B1 (en) * | 2015-09-16 | 2017-03-07 | Sansa Corporation (Barbados) Inc. | Inhalable nicotine formulations and methods of making and using the same |
US10149844B2 (en) | 2015-09-16 | 2018-12-11 | Philip Morris Products S.A. | Inhalable nicotine formulations, and methods of making and using thereof |
WO2017218341A1 (en) | 2016-06-17 | 2017-12-21 | Axon Enterprise, Inc. | Systems and methods for aligning event data |
MX2018015119A (es) | 2016-06-30 | 2019-04-15 | Philip Morris Products Sa | Particulas de nicotina. |
US20190133940A1 (en) * | 2016-06-30 | 2019-05-09 | Philip Morris Products S.A. | Nicotine particles and compositions |
JP7085538B2 (ja) * | 2016-10-14 | 2022-06-16 | パルマトリックス オペレーティング カンパニー,インコーポレイテッド | 抗真菌薬乾燥粉末 |
MX2019010263A (es) * | 2017-03-07 | 2019-10-09 | Philip Morris Products Sa | Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas. |
US11590298B2 (en) | 2017-06-02 | 2023-02-28 | Csp Technologies, Inc. | Inhaler and methods of using and making same |
CN109200034A (zh) * | 2017-06-30 | 2019-01-15 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的组合物及其制备方法 |
CN115919780A (zh) | 2017-09-22 | 2023-04-07 | 维克图拉公司 | 含有硬脂酸镁的干粉组合物 |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
EP3735223A4 (en) | 2018-01-05 | 2021-10-13 | Impel Neuropharma Inc. | INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE |
CN112451509B (zh) * | 2020-12-19 | 2023-03-07 | 沈阳药科大学 | 一种川丁特罗吸入粉雾剂及其制备方法 |
WO2023069028A1 (en) * | 2021-10-20 | 2023-04-27 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
US12005185B2 (en) * | 2021-12-17 | 2024-06-11 | Belhaven BioPharma Inc. | Medical counter measures including dry powder formulations and associated methods |
WO2023128913A1 (en) * | 2021-12-31 | 2023-07-06 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
WO2024009079A1 (en) | 2022-07-04 | 2024-01-11 | Hovione Scientia Limited | Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation |
CN115060832B (zh) * | 2022-08-18 | 2022-11-29 | 上海奥科达生物医药科技有限公司 | 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687773A (en) | 1983-03-28 | 1987-08-18 | Mclean Hospital | (+)-N-N-propylnorapomorphine and selective limbic activity |
EP0470154B1 (en) | 1989-04-28 | 1996-06-05 | Riker Laboratories, Inc. | Dry powder inhalation device |
JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
US5292520A (en) | 1990-09-13 | 1994-03-08 | Akzo N.V. | Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
AR002009A1 (es) | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
FR2747311B1 (fr) | 1996-04-10 | 1998-08-14 | Pf Medicament | Inhalateur a poudre et a air comprime |
PT954282E (pt) | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | Preparacao de particulas para inalacao |
US6051257A (en) | 1997-02-24 | 2000-04-18 | Superior Micropowders, Llc | Powder batch of pharmaceutically-active particles and methods for making same |
EP0931595A1 (en) | 1998-01-26 | 1999-07-28 | Imra Europe S.A. | A device for spraying a liquid |
US6257233B1 (en) | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
CZ303154B6 (cs) | 1998-11-13 | 2012-05-09 | Jagotec Ag | Suchá prášková formulace k inhalaci obsahující stearát horecnatý |
GB9827145D0 (en) * | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
PL196951B1 (pl) | 1999-03-05 | 2008-02-29 | Chiesi Farma Spa | Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika |
JP4722295B2 (ja) | 1999-05-27 | 2011-07-13 | エイカスフィアー・インコーポレーテッド | 多孔性薬剤マトリクスおよびその製造方法 |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
GB2353222B (en) | 1999-06-23 | 2001-09-19 | Cambridge Consultants | Inhalers |
US20010036481A1 (en) | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US6586008B1 (en) | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
JP2001072586A (ja) | 1999-09-06 | 2001-03-21 | Nikken Chem Co Ltd | 吸入用粉末製剤及びその製造方法 |
JP2001151673A (ja) | 1999-09-06 | 2001-06-05 | Nikken Chem Co Ltd | 吸入用粉末製剤の製造方法 |
CN102584799A (zh) | 1999-09-16 | 2012-07-18 | 田边三菱制药株式会社 | 含氮的6-员芳香环化合物 |
FI20002217A (fi) | 1999-12-30 | 2001-07-01 | Orion Yhtymae Oyj | Inhalaatiopartikkelit |
GB0008411D0 (en) * | 2000-04-05 | 2000-05-24 | Vectura Ltd | Pharmaceutical preparations and their manufacture |
CN1471395A (zh) | 2000-04-07 | 2004-01-28 | ����ҽҩƷ����˾ | 阿扑吗啡衍生物及其使用方法 |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
DE60128902T2 (de) | 2000-04-17 | 2008-02-14 | Vectura Ltd., Chippenham | Formulierungen zur verwendung in inhalationsvorrichtungen |
GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
GB0010709D0 (en) * | 2000-05-03 | 2000-06-28 | Vectura Ltd | Powders for use a in dry powder inhaler |
WO2002000197A1 (en) | 2000-06-27 | 2002-01-03 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
GB2364919A (en) | 2000-07-21 | 2002-02-13 | Cambridge Consultants | Inhalers |
AU2001277230A1 (en) | 2000-08-01 | 2002-02-13 | Inhale Therapeutic Systems, Inc. | Apparatus and process to produce particles having a narrow size distribution andparticles made thereby |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US20020086876A1 (en) | 2000-11-15 | 2002-07-04 | Ruff Dustin D. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
EP1341536A4 (en) | 2000-11-15 | 2007-08-01 | Tap Pharmaceutical Prod Inc | TREATMENT OF SEXUAL DYSFUNCTION CAUSED BY ANTIDEPRESSIVE MEDICATION BY APOMORPHINE |
EP2283818B1 (en) | 2000-11-30 | 2017-08-02 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US20040052733A1 (en) * | 2000-11-30 | 2004-03-18 | Staniforth John Nicholas | Pharmaceutical compositions for inhalation |
NZ526059A (en) | 2000-11-30 | 2005-05-27 | Vectura Ltd | Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition |
WO2002043700A2 (en) * | 2000-11-30 | 2002-06-06 | Vectura Limited | Particles for use in a pharmaceutical composition |
DK1353647T3 (da) | 2000-12-27 | 2011-06-14 | Gilead Sciences Inc | Inhalerbar aztreonam til behandling og forebyggelse af bakterielle lungeinfektioner |
GB0109384D0 (en) * | 2001-04-12 | 2001-05-30 | Vectura Ltd | Pharmaceutical products, preparation and uses thereof |
WO2002089880A2 (en) | 2001-05-10 | 2002-11-14 | Vectura Delivery Devices Limited | Inhalers |
CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
JP2005506323A (ja) * | 2001-09-05 | 2005-03-03 | ベクトゥラ・リミテッド | 経口送達用機能性散剤 |
EP1490031A1 (en) * | 2002-03-07 | 2004-12-29 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
US20040003341A1 (en) | 2002-06-20 | 2004-01-01 | Koninklijke Philips Electronics N.V. | Method and apparatus for processing electronic forms for use with resource constrained devices |
JP2006506357A (ja) * | 2002-10-11 | 2006-02-23 | ヴェクトゥラ リミテッド | 有機高分子物質との組み合わせで無機粒子を含み、かつ固体の網目状マトリックスを形成する医薬賦形剤、その組成物、製造および使用 |
US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
US20040204439A1 (en) | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
EP1613323A1 (en) | 2003-04-14 | 2006-01-11 | Vectura Limited | Pharmaceutical compositions comprising apomorhine for pulmonary inhalation |
WO2004093848A2 (en) * | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
WO2005025535A2 (en) * | 2003-09-15 | 2005-03-24 | Vectura Limited | Methods for preparing pharmaceutical compositions |
GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
GB0330255D0 (en) | 2003-12-31 | 2004-02-04 | Vectura Ltd | Multiparticulate formulations for oral delivery |
GB0408308D0 (en) | 2004-04-14 | 2004-05-19 | Vectura Ltd | Pharmaceutical compositions |
GB0409703D0 (en) * | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
GB0426301D0 (en) | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
-
2004
- 2004-11-23 GB GBGB0425758.0A patent/GB0425758D0/en not_active Ceased
-
2005
- 2005-11-23 EP EP05808842A patent/EP1814521B1/en active Active
- 2005-11-23 HU HUE10179073A patent/HUE027465T2/en unknown
- 2005-11-23 JP JP2007542131A patent/JP5339401B2/ja active Active
- 2005-11-23 PT PT101515765T patent/PT2174653E/pt unknown
- 2005-11-23 EP EP15173932.3A patent/EP2949317B1/en not_active Revoked
- 2005-11-23 EP EP10151576.5A patent/EP2174653B1/en active Active
- 2005-11-23 US US11/791,385 patent/US20080127972A1/en not_active Abandoned
- 2005-11-23 CN CNA2005800470735A patent/CN101106975A/zh active Pending
- 2005-11-23 DE DE602005019192T patent/DE602005019192D1/de active Active
- 2005-11-23 ES ES05808842T patent/ES2340599T3/es active Active
- 2005-11-23 PT PT101790731T patent/PT2311434E/pt unknown
- 2005-11-23 CN CN201410314552.XA patent/CN104146960A/zh active Pending
- 2005-11-23 SI SI200532009T patent/SI2311434T1/sl unknown
- 2005-11-23 SI SI200531874T patent/SI2174653T1/sl unknown
- 2005-11-23 PL PL10179073T patent/PL2311434T3/pl unknown
- 2005-11-23 DK DK10151576.5T patent/DK2174653T3/da active
- 2005-11-23 CA CA2589514A patent/CA2589514C/en active Active
- 2005-11-23 AT AT05808842T patent/ATE456363T1/de active
- 2005-11-23 DK DK10179073.1T patent/DK2311434T3/en active
- 2005-11-23 WO PCT/GB2005/050211 patent/WO2006056812A1/en active Application Filing
- 2005-11-23 PL PL05808842T patent/PL1814521T3/pl unknown
- 2005-11-23 EP EP10179073.1A patent/EP2311434B1/en not_active Revoked
- 2005-11-23 ES ES10151576.5T patent/ES2490240T3/es active Active
- 2005-11-23 PL PL10151576T patent/PL2174653T3/pl unknown
- 2005-11-23 PT PT05808842T patent/PT1814521E/pt unknown
- 2005-11-23 ES ES10179073.1T patent/ES2548884T3/es active Active
-
2011
- 2011-04-12 US US13/085,200 patent/US9585834B2/en active Active
- 2011-07-13 JP JP2011154690A patent/JP5579669B2/ja active Active
-
2014
- 2014-06-11 IN IN4336CHN2014 patent/IN2014CN04336A/en unknown
-
2015
- 2015-08-11 US US14/823,484 patent/US9642800B2/en active Active
-
2017
- 2017-04-10 US US15/483,988 patent/US20170216203A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2311434T1 (sl) | Formulacije za inhalator suhega praška, ki vsebujejo površinsko modificirane delce z aditivi proti sprijemanju | |
WO2008084312A3 (en) | Micronised particles of low-dosage strength active agents for powder formulations for inhalation | |
TW200613479A (en) | Coating formulation having improved rheological properties | |
WO2007053197A3 (en) | Nanoparticulate acetaminophen formulations | |
WO2005025535A3 (en) | Methods for preparing pharmaceutical compositions | |
MX2009005727A (es) | Nanoparticulas de entidad anfifilica. | |
MX336930B (es) | Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas. | |
NO20025873L (no) | Meget effektiv levering av en stor terapeutisk mengde aerosol | |
IL218317A (en) | Use of 15-il polypeptide preparations and 15-il complexes for the preparation of cancer drugs | |
PL1663155T3 (pl) | Kompozycje suchego proszku zawierające współmielone strumieniowo cząstki do inhalacji dopłucnej | |
MX2008011072A (es) | Particulas de suministro que contienen un agente benefico. | |
MY150531A (en) | Anti-cd79b antibodies and immunoconjugates and methods of use | |
MY155299A (en) | Oral dosage composition | |
JO2430B1 (en) | Pharmaceutical formulas for dry powder inhalations in the form of solid pellets | |
TNSN05047A1 (en) | Inhalation composition | |
WO2006008517A3 (en) | Use of dry powder compositions for pulmonary delivery | |
MX371008B (es) | Polvos pulmonares de ultra baja densidad. | |
HN2008000964A (es) | Enmascaramiento del sabor de polvos | |
MX368774B (es) | Nueva dosificación y formulación. | |
ATE453382T1 (de) | Pulver zur nasalen verabreichung von wirkstoffen | |
WO2005041922A3 (en) | Composition | |
EA200500389A1 (ru) | Композиции для ингаляции | |
TW200730170A (en) | Micronised azodicarbonamide, and the preparation and use thereof | |
EA200900464A1 (ru) | Фармацевтическая композиция для ингаляции | |
WO2008066810A3 (en) | Pleasant tasting dry powder compositions suitable for pulmonary delivery |